Drug
Advm 043
Advm 043: highest development phase Phase 1/2, developed by Adverum Biotechnologies. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Adverum Biotechnologies
Trials
| Drug | Phase | Indication |
|---|---|---|
| ADVM-043 NCT02168686 | Phase 1/2 | Alpha 1-Antitrypsin Deficiency |
Latest
No recent events.
Follow Advm 043 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.